Dabigatran
Prabashni Reddy, Julie K. Atay, Leslie G. Selbovitz et al. · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · 2011
Dabigatran etexilate is the first commercially available oral direct thrombin inhibitor. A single trial has studied patients at risk for stroke associated with nonvalvular atrial fibrillation; in this trial, dabigatran 150 mg twice a day met the criteria for superiority over warfarin in preventing stroke and systemic embolism while reducing the rate of hemorrhagic stroke with a similar risk of major bleeding. For the treatment of venous thromboembolism, dabigatran 150 mg twice a day had comparable efficacy and safety versus warfarin. In contrast, dabigatran was less effective than enoxaparin 30 mg twice a day in venous thromboembolism prevention in orthopedic surgery. Advantages of dabigatran over warfarin include its lack of need for routine laboratory monitoring, a fixed-dose regimen, and potentially fewer clinically important drug interactions. Concerns include higher incidences of dyspepsia and gastrointestinal bleeding, twice-daily dosing, and lack of effective antidote. Additional drawbacks include higher drug cost versus warfarin, accumulation in case of renal impairment, higher discontinuation rates due to adverse events, and limited long-term safety and trial data. From a payer perspective, overall costs will be higher with dabigatran compared with warfarin, but dabigatran does meet the threshold to be considered a cost-effective therapy. In addition, the lack of need for regular laboratory monitoring is a quality of life advantage for patients on dabigatran. These observations suggest that dabigatran is a valuable addition to the therapeutic armamentarium for stroke prevention in selected patients with atrial fibrillation although caution should be exercised given the limited data on this agent and higher cost.
Cited by 13 works. doi:10.1097/hpc.0b013e3182315c03
Authors
- Prabashni Reddy
- Julie K. Atay
- Leslie G. Selbovitz
- Jean M. Connors
- Gregory Piazza
- Caroline Cole Block
- Paul A. Arpino
- Nancy Berliner
- Adolph M. Hutter
- Michael A. Fischer
- David J. Kuter
- James I. Weitzman
- Geoffery K. Sherwood
- Avraham Almozlino
- Robert Patrick Giugliano
References
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- Guidelines for the management of atrial fibrillation
- Oral Rivaroxaban for Symptomatic Venous Thromboembolism
- Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
- Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
- Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
- Antithrombotic Therapy in Atrial Fibrillation
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
- Newly Identified Events in the RE-LY Trial